Healthy volunteer study sheds light on potential liver disease drug metabolism

NCT ID NCT03159390

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in 20 healthy adults aged 40-70 examined how the body breaks down ornithine phenylacetate, a compound being explored for liver disease. Researchers used special tracers and collected blood, urine, and muscle samples to track its metabolism. The goal was to understand how the drug is processed, not to test any treatment effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ornithine phenylacetate

What this could lead to

If this study clarifies how ornithine phenylacetate is metabolized, it could help design future treatments for liver disease.

What could go wrong

This was a small, early-stage study in healthy volunteers, not patients. The results may not apply to people with liver disease, and no therapeutic benefit was tested.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas A&M University-CTRAL

    College Station, Texas, 77843-4253, United States